GeneCentric Therapeutics, founded in Durham, NC, is a molecular diagnostic technology provider focused on developing and commercializing advanced cancer diagnostics and therapies. Their core mission is to enhance precision medicine by identifying the right treatments for the right patients through RNA-based informatics. The company offers unique platform technologies, including the Lung Subtype Platform (LSP), which stratifies lung cancer patients into subtypes for better therapeutic selection. Their market focus is on oncologists and patients seeking more accurate and effective cancer treatment options.

Notable affiliations include a partnership with Laboratory Corporation of America Holdings (LabCorp), which has independently developed and made available the first application of LSP. GeneCentric's RNA-based diagnostics provide a more comprehensive understanding of tumor biology compared to traditional DNA testing. Key achievements include the successful deployment of their RNA-based informatics pipeline, which has significantly advanced the development of precision cancer therapeutics. The overall impact of GeneCentric Therapeutics lies in its contribution to more precise and personalized cancer care, improving outcomes for patients worldwide.